01/10/2025
7:36 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/11/2024
3:15 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/15/2024
4:05 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
4:46 PM | 4D Molecular Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/14/2024
2:15 PM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
11/14/2024
8:13 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
11/13/2024
3:33 PM | 4D Molecular Therapeutics (Issuer)
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
LAMPERT MARK N (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
11/13/2024
3:17 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/13/2024
3:08 PM | 4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
11/12/2024
11:12 AM | 4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G/A | |
11/08/2024
1:17 PM | 4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
| Form SC 13G/A | |
11/06/2024
5:07 PM | 4D Molecular Therapeutics (Subject)
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
| Form SC 13G | |
11/04/2024
9:55 AM | 4D Molecular Therapeutics (Subject)
VANGUARD GROUP INC (Filed by)
| Form SC 13G | |
10/21/2024
3:11 PM | 4D Molecular Therapeutics (Subject)
BlackRock, Inc. (Filed by)
| Form SC 13G/A | |
09/18/2024
4:46 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:06 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/23/2024
5:04 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/18/2024
7:22 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/17/2024
5:04 AM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/15/2024
5:13 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/12/2024
4:46 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/10/2024
4:17 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024
4:11 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2024
3:43 PM | 4D Molecular Therapeutics (Subject)
Bizily Scott (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/26/2024
4:07 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/25/2024
3:44 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144/A | |
06/24/2024
4:39 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/07/2024
4:04 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
06/07/2024
4:07 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/23/2024
7:45 PM | 4D Molecular Therapeutics (Issuer)
Tomasello Shawn (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:10 PM | 4D Molecular Therapeutics (Issuer)
GRAY SUSANNAH (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:11 PM | 4D Molecular Therapeutics (Issuer)
MILLIGAN JOHN F (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:12 PM | 4D Molecular Therapeutics (Issuer)
Miller-Rich Nancy (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:16 PM | 4D Molecular Therapeutics (Issuer)
THEUER CHARLES (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/23/2024
6:17 PM | 4D Molecular Therapeutics (Issuer)
Chacko Jacob (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/20/2024
7:35 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
3:22 PM | 4D Molecular Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/09/2024
3:09 PM | 4D Molecular Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/18/2024
7:48 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/10/2024
3:05 PM | 4D Molecular Therapeutics (Filer)
| Form DEF 14A | |
04/10/2024
3:06 PM | 4D Molecular Therapeutics (Filer)
| Form DEFA14A | |
|
04/10/2024
3:07 PM | 4D Molecular Therapeutics (Filer)
| Form ARS | |
04/03/2024
6:18 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/29/2024
3:52 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/20/2024
3:40 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:01 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
4:15 PM | 4D Molecular Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
02/21/2024
4:41 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
7:51 PM | 4D Molecular Therapeutics (Subject)
Venrock Healthcare Capital Partners III, L.P. (Filed by)
| Form SC 13G/A | |
02/14/2024
8:56 AM | 4D Molecular Therapeutics (Subject)
BIOTECHNOLOGY VALUE FUND L P (Filed by)
| Form SC 13G/A | |
02/14/2024
7:43 AM | 4D Molecular Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
| Form SC 13G/A | |
02/13/2024
9:56 AM | 4D Molecular Therapeutics (Subject)
JANUS HENDERSON GROUP PLC (Filed by)
| Form SC 13G/A | |
02/12/2024
8:04 PM | 4D Molecular Therapeutics (Issuer)
Bizily Scott (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/12/2024
7:22 PM | 4D Molecular Therapeutics (Issuer)
Kirn David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/08/2024
3:50 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/07/2024
7:32 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/07/2024
6:42 PM | 4D Molecular Therapeutics (Issuer)
Kim Robert Young (Reporting)
| Form 3/A | |
02/05/2024
4:27 PM | 4D Molecular Therapeutics (Filer)
| Form 424B5 | |
02/05/2024
3:35 PM | 4D Molecular Therapeutics (Filer)
| Form S-3ASR | |
01/25/2024
3:59 PM | 4D Molecular Therapeutics (Subject)
BlackRock Inc. (Filed by)
| Form SC 13G/A | |
01/23/2024
3:50 PM | 4D Molecular Therapeutics (Subject)
Kirn David (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
